Sexually transmitted infections and clinical features in monkeypox (mpox) patients in Madrid, Spain
Alfredo Maldonado-Barrueco, Claudia Sanz-González, Almudena Gutiérrez-Arroyo, David Grandioso-Vas, Patricia Roces-Álvarez, Elena Sendagorta-Cudos, Iker Falces‐Romero, Jesús Mingorance, Julio García‐Rodríguez, Inmaculada Quiles‐Melero
Abstract
Since the beginning of the monkeypox (mpox) virus outbreak in May 2022, there has been an increase in the number of cases worldwide in the setting of sexual transmission. We have tested by real-time PCR 187 mpox patients, of which 157 patients were screened for sexually transmitted infections (STI) in 245 samples. Thirty-six pathogens were detected in 30 patients: herpes simplex virus (HSV-I/II, 12/36, 33.3%), Neisseria gonorrhoeae (NG, 9/36, 25%), Chlamydia trachomatis (CT, 5/36, 13.8%), Chlamydia trachomatis-lymphogranuloma venereum (CT-LGV, 3/36, 8.3%), Treponema pallidum (TP, 4/36, 11.1%) and Mycoplasma genitalium (MG, 3/36, 8.3%). Screening of STI is recommended in mpox patients for the differential diagnosis of the main infections of sexual tract especially in patients with rectal involvement.